Selection and anti-cancer effects of siRNAs targeting HMGA2 gene.
- Author:
Qi-Zhao WANG
1
;
Yu-Hua GONG
;
Ying-Hui LÜ
;
Ling-Na FEI
;
Hui-Jie LIU
;
Yong DIAO
;
Rui-An XU
Author Information
1. Institute of Molecular Medicine, Huaqiao University, Quanzhou 362021, China.
- Publication Type:Journal Article
- MeSH:
Apoptosis;
Cell Line, Tumor;
Cell Movement;
Cell Proliferation;
Colony-Forming Units Assay;
Gene Silencing;
Genetic Therapy;
HMGA2 Protein;
genetics;
metabolism;
Humans;
Interferons;
metabolism;
Lung Neoplasms;
genetics;
metabolism;
pathology;
Point Mutation;
RNA, Messenger;
metabolism;
RNA, Small Interfering;
genetics;
Transfection
- From:
Acta Pharmaceutica Sinica
2011;46(12):1444-1450
- CountryChina
- Language:Chinese
-
Abstract:
High mobility group A2 protein (HMGA2), an architectural factor, is highly expressed in various cancer types including lung cancers. It is a candidate target for cancer therapy. RNAi is an effective gene silencing method with low cost and less time-consuming. It is possible to exploit this technology in therapy. Here, 5 siRNAs targeting Hmga2 gene (HMGA2 siRNA1-5) were designed and synthesized. MTT assay, colony formation assay, transwell assay and flow cytometry were used to evaluate the effects of these siRNAs on lung cancer cell lines (NCI-H446 and A549). Results from cell proliferation, clone formation, migration and apoptosis showed that HMGA2 siRNA1, 3, 5 could affect these aspects for both lung cancer cell lines. Among the five siRNAs, HMGA2 siRNA5 showed the greatest inhibition effects. The inhibition effects of HMGA2 siRNA5 are sequence specific and are not due to the induction of interferon response. Taken together, siRNAs targeting Hmga2 gene are potential candidates for lung cancer gene therapy.
